- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07784855
Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer
WVU011625: The Role of Scheduled Intravenous Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer
Patients undergoing concurrent chemoradiotherapy (CCRT) for head and neck squamous cell carcinoma frequently experience treatment-related toxicities including mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. Many of these toxicities may be exacerbated by dehydration and are commonly managed with clinician-directed intravenous (IV) hydration. This study will evaluate whether scheduled IV hydration reduces the incidence and severity of treatment-related toxicities compared with clinician assessment-based hydration. Participants will be randomized 1:1 to scheduled IV hydration or clinician assessment-based IV hydration beginning in Week 3 of concurrent chemoradiotherapy and continuing through one week following completion of chemoradiotherapy.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Nina Moore
- Numéro de téléphone: 304-293-2991
- E-mail: nina.moore@hsc.wvu.edu
Sauvegarde des contacts de l'étude
- Nom: Ella Betler
- Numéro de téléphone: 304-293-4273
- E-mail: eibetler@hsc.wvu.edu
Lieux d'étude
-
-
West Virginia
-
Bridgeport, West Virginia, États-Unis, 26330
- Pas encore de recrutement
- WVU Medicine United Hospital Center
-
Contact:
- Sabrina Rexroad
- Numéro de téléphone: 681-342-1000
- E-mail: sabrina.rexroad1@wvumedicine.org
-
Martinsburg, West Virginia, États-Unis, 25401
- Pas encore de recrutement
- WVU Medicine Berkeley Medical Center
-
Contact:
- Valli White
- Numéro de téléphone: 304-264-1220
- E-mail: valli.white@wvumedicine.org
-
Morgantown, West Virginia, États-Unis, 26506
- Recrutement
- West Virginia University Cancer Institute
-
Contact:
- Nina Moore
- Numéro de téléphone: 304-293-2991
- E-mail: nina.moore@hsc.wvu.edu
-
Chercheur principal:
- David Clump, MD, PhD
-
Chercheur principal:
- Sidra Najeeb, MD
-
Contact:
- Ella Betler
- Numéro de téléphone: 304-293-4273
- E-mail: eibetler@hsc.wvu.edu
-
Parkersburg, West Virginia, États-Unis, 26101
- Pas encore de recrutement
- WVU Medicine Camden Clark Medical Center
-
Contact:
- Layla Tannaoury
- Numéro de téléphone: 304-424-2585
- E-mail: Layla.tannoury@wvumedicine.org,
-
Princeton, West Virginia, États-Unis, 24740
- Pas encore de recrutement
- WVU Medicine Princeton Community Hospital
-
Contact:
- Melissa Boggess
- Numéro de téléphone: 304-487-7515
- E-mail: melissa.boggess1@wvumedicine.org
-
Wheeling, West Virginia, États-Unis, 26003
- Pas encore de recrutement
- WVU Medicine Wheeling Hospital
-
Contact:
- Maher Kali
- Numéro de téléphone: 304-243-7045
- E-mail: maher.kali@wvumedicine.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- ECOG 0-2
- Non-nasopharyngeal squamous cell carcinoma of oral cavity, oropharynx, hypopharynx, larynx primary
- Planned for concurrent chemoradiotherapy (CCRT) with standard-of-care cisplatin-based regimen (IV cisplatin 100mg/m2 once every three weeks for up to three doses or IV cisplatin 40mg/m2 weekly) with concurrent radiotherapy (treatment duration approximately 6-7 weeks, per institutional standards).
- The use of immunotherapy in combination with CCRT is permitted and does not affect eligibility or group assignment.
Exclusion Criteria:
- Nasopharyngeal squamous cell carcinomas, nasal cavity and paranasal sinus squamous cell carcinomas.
- History of congestive heart failure.
- Dependency on enteral nutrition and hydration prior to enrollment.
- Use of diuretics that cannot be safely held during study treatment (participants who are able to temporarily discontinue diuretics during treatment are eligible).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Scheduled IV Hydration
Participants will receive scheduled IV hydration approximately twice per week throughout the treatment period. IV fluids will continue even if chemoradiotherapy infusion is held due to toxicities or cytopenias. |
Normal saline (0.9% sodium chloride) 1L of saline will be administered at each hydration visit. Participants will receive IV fluids on a planned schedule of twice a week, starting in Week 3 of chemoradiation treatment and continuing for one week after treatment is completed. |
|
Autre: Clinician Assessment-Based IV Hydration
Participants will receive IV fluids (normal saline) only as clinically indicated and ordered by their treating clinician, per standard of care. IV fluids may continue if chemoradiotherapy infusion is held due to toxicities or cytopenias, at the discretion of the treating clinician. |
IV fluids (normal saline (0.9% sodium chloride)) only as clinically indicated and ordered by their treating clinician, per standard of care. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of at least one Grade ≥3 Treatment-Related Toxicities of Interest
Délai: From initiation of concurrent chemoradiotherapy through completion of treatment (approximately 6-7 weeks)
|
Incidence of participants experiencing at least one Grade ≥3 according to National Cancer Institute Common Terminology Criteria for Adverse Events v6.0 (NCI CTCAE) treatment-related toxicity of interest, including mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, or trismus, during concurrent chemoradiotherapy. |
From initiation of concurrent chemoradiotherapy through completion of treatment (approximately 6-7 weeks)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidences of Individual Treatment-Related Toxicities of Interest
Délai: From initiation of concurrent chemoradiotherapy through completion of treatment (approximately 6-7 weeks)
|
Incidence of treatment-related mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus of any grade, as assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 6.0. |
From initiation of concurrent chemoradiotherapy through completion of treatment (approximately 6-7 weeks)
|
|
Incidence of Enteric Tube Placement
Délai: From initiation of treatment through 6 months after completion of chemoradiotherapy
|
Incidence of participants requiring enteric feeding tube placement during treatment and follow-up. |
From initiation of treatment through 6 months after completion of chemoradiotherapy
|
|
Incidence of Hematologic Toxicities
Délai: Weeks 3-6 of concurrent chemoradiotherapy
|
Incidence of leukopenia, anemia, and thrombocytopenia assessed during weeks 3-6 of concurrent chemoradiotherapy treatment as assessed according to NCI CTCAE v6.0. |
Weeks 3-6 of concurrent chemoradiotherapy
|
|
Residual Grade of Toxicities of Interest at 3 Months
Délai: 3 months after completion of chemoradiotherapy
|
Residual severity (NCI CTCAE v6.0 Grades 0-5) of mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. |
3 months after completion of chemoradiotherapy
|
|
Residual grade of Toxicities of Interest at 6 Months
Délai: 6 months after completion of chemoradiotherapy
|
Residual severity (NCI CTCAE v6.0 Grades 0-5) of mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. |
6 months after completion of chemoradiotherapy
|
|
Complete Recovery of Toxicities of Interest at 3 Months
Délai: 3 months after completion of chemoradiotherapy
|
Incidence of participants with complete recovery (NCI CTCAE v6.0 Grade 0) from mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. |
3 months after completion of chemoradiotherapy
|
|
Complete Recovery of Toxicities of Interest at 6 Months
Délai: 6 months after completion of chemoradiotherapy
|
Incidence of participants with complete recovery (NCI CTCAE v6.0 Grade 0) from mucositis, dysphagia, acute kidney injury, pain, constipation, dermatitis, xerostomia, and trismus. |
6 months after completion of chemoradiotherapy
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Sidra Najeeb, MD, WVU Cancer Center
- Chaise d'étude: David Clump, MD, PhD, WVU Cancer Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STUDY00000501
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified individual participant data collected during the study, including demographic information, eligibility criteria, treatment/exposure data, outcome assessments, and relevant follow-up data, will be made available to qualified researchers. Data that could directly identify participants will not be shared.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .